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Candida rugosa is a fungus that appears to be emerging as a cause of infection in some geographic regions.
We utilized the extensive database of the ARTEMIS DISK Antifungal Surveillance Program to describe the
geographic and temporal trends in the isolation of C. rugosa from clinical specimens and the in vitro
susceptibilities of 452 isolates to fluconazole and voriconazole. C. rugosa accounted for 0.4% of 134,715 isolates
of Candida, and the frequency of isolation increased from 0.03% to 0.4% over the 6.5-year study period (1997
to 2003). C. rugosa was most common in the Latin American region (2.7% versus 0.1 to 0.4%). Decreased
susceptibility to fluconazole (40.5% susceptible) was observed in all geographic regions; however, isolates from
Europe and North America were much more susceptible (97 to 100%) to voriconazole than those from other
geographic regions (55.8 to 58.8%). C. rugosa was most often isolated from blood and urine in patients
hospitalized at the Medical and Surgical inpatient services. Notably, bloodstream isolates were the least
susceptible to both fluconazole and voriconazole. C. rugosa should be considered, along with the established
pathogens Candida krusei and Candida glabrata, as a species of Candida with reduced susceptibility to the azole
antifungal agents.
Although quite rare as a cause of invasive fungal infections
(9), Candida rugosa has recently been cited as a possible
“emerging” fungal pathogen (6). Fungemia due to this species
of Candida was unrecognized prior to 1985, when catheter-
related fungemia was reported in two different institutions in
the United States (15, 21). Subsequently, Dube et al. (3) re-
ported 15 episodes of candidemia due to C. rugosa in burn
patients receiving topical nystatin treatment in a U.S. hospital.
No obvious source of the infections was found; however, the
isolates were shown to be resistant to nystatin and to have
reduced susceptibility to both amphotericin B and fluconazole.
More recently, a cluster of six episodes of candidemia caused
by C. rugosa was reported in Brazil (2). Two of the episodes
represented breakthrough infections in patients receiving am-
photericin B treatment, and all four patients treated with this
agent died. Follow-up surveillance revealed that C. rugosa was
a frequent colonizer of high-risk patients and accounted for
44% of 32 consecutive episodes of fungemia at one Brazilian
tertiary care center (17). Those reports suggest that C. rugosa
may exhibit decreased susceptibility to both polyenes and flu-
conazole, may cause catheter-related fungemia in seriously ill
patients, may be transmitted from patient to patient in the
hospital setting, and may be endemic in certain institutions (6).
Aside from these few observations, there is a paucity of
information regarding the epidemiology, frequency of occur-
rence, and antifungal susceptibility profile of this uncommon
species of Candida (9). In the present study, we have taken
advantage of the extensive database compiled by the ARTEMIS
DISK Antifungal Surveillance Program (11) to describe the
geographic and temporal trends in the isolation of C. rugosa
from clinical specimens collected from 127 medical centers
between 1997 and 2003, the types of specimens and clinical
services in which C. rugosa infections are recognized, and the in
vitro susceptibilities of 452 clinical isolates, including 74 blood-
stream infection (BSI) isolates, of this species to both flucon-
azole and voriconazole as determined by standardized disk
diffusion testing. This report will serve as the largest study of C.
rugosa isolates to date.
MATERIALS AND METHODS
Organisms and test sites. A total of 134,715 isolates of Candida spp. from 127
different medical centers in Asia (23 sites), Latin America (16 sites), Europe (74
sites), the Middle East (2 sites), and North America (12 sites) were isolated and
identified between June 1997 and December 2003. All Candida spp. considered
pathogens by the respective attending physicians from all body sites (e.g., blood,
normally sterile body fluids, deep-tissue biopsy, genital tract, gastrointestinal
tract, respiratory tract, skin, and soft tissue) and isolates from all in-hospital and
outpatient locations during the study period were tested. Data for C. rugosa were
stratified by year of isolation, geographic region, clinical service (hospital loca-
tion), and specimen type. Candida spp. considered by the local-site investigator
to be colonizers, that is, not associated with clinical infection, were excluded, as
were duplicate isolates (the same species and the same susceptible-resistant
biotype profile within any 7-day period). Identification of isolates was performed
in accordance with each site’s routine methods.
Susceptibility test methods. Disk diffusion testing of fluconazole and voricon-
azole was performed as described previously (10–12) and in accordance with
Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS) docu-
ment M44-A (5). Agar plates (150-mm diameter) containing Mueller-Hinton
agar (obtained locally at all sites) supplemented with 2% glucose and 0.5 g of
methylene blue per ml at a depth of 4.0 mm were used. The agar surface was
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inoculated by using a swab dipped in a cell suspension adjusted to the turbidity
of a 0.5 McFarland standard. Fluconazole (25-g) and voriconazole (1-g) disks
(Becton Dickinson, Sparks, Md.) were placed onto the surfaces of the plates, and
the plates were incubated in air at 35 to 37°C and read at 18 to 24 h. Zone
diameter endpoints were read at 80% growth inhibition by using the BIOMIC
image analysis plate reader system (version 5.9; Giles Scientific, Santa Barbara,
Calif.) (4, 10–12).
The interpretive criteria for the fluconazole and voriconazole disk diffusion
tests were those of the CLSI (5, 13, 14) and are as follows: susceptible (S), zone
diameters of 19 mm (fluconazole) and 17 mm (voriconazole); susceptible-
dose dependent (SDD), zone diameters of 15 to 18 mm (fluconazole) and 14 to
16 mm (voriconazole); and resistant (R), zone diameters of 14 mm (flucon-
azole) and 13 mm (voriconazole). The corresponding MIC breakpoints (5, 13,
14) are as follows: S, MIC of 8 g/ml (fluconazole) and 1 g/ml (voricon-
azole); SDD, MIC of 16 to 32 g/ml (fluconazole) and 2 g/ml (voriconazole);
R, MIC of 64 g/ml (fluconazole) and 4 g/ml (voriconazole).
QC. Quality control (QC) was performed in accordance with CLSI document
M44-A (5) by using Candida albicans ATCC 90029 and Candida parapsilosis
ATCC 22019. A total of 5,865 and 5,484 QC results were obtained for flucon-
azole and voriconazole, respectively, more than 99% of which were within the
acceptable limits. External quality assurance was performed by testing more
than 2,900 isolates from blood and normally sterile-site infections against
both fluconazole and voriconazole by ARTEMIS participating laboratories
and by the central reference laboratory (10, 12). Excellent agreement was
seen between participating and reference laboratories, ensuring the accuracy
of the ARTEMIS data.
Analysis of results. All disk zone diameters were read by electronic image
analysis and interpreted and recorded with a BIOMIC Plate Reader system
(Giles Scientific). Test results were sent by e-mail to Giles Scientific for analysis.
The zone diameter susceptibility categories (S, SDD, or R) and QC test results
were all recorded electronically. Patient and doctor names, duplicate test results
(the same patient, the same species, and same biotype result), and uncontrolled
results were automatically eliminated by the BIOMIC system prior to analysis.
RESULTS
Isolation of C. rugosa over time and by geographic region. A
total of 134,715 isolates of Candida spp. were isolated and
identified at 127 study sites between June 1997 and December
2003 (11). C. rugosa ranked ninth among more than 16 species
of Candida, accounting for approximately 0.4% of all isolates
(11). The frequency of isolation of C. rugosa increased by more
than 10-fold over the course of the study (0.03% to 0.4%) (11).
Data for the various sites contributing isolate results to the
study were available for the time period of 2001 through 2003
(Table 1). C. rugosa represented 0.6% of the 75,761 isolates
collected during this time period and was most common in the
Latin American region (Table 1).
Geographic variation in susceptibility of C. rugosa to flucon-
azole and voriconazole. Table 2 presents the in vitro suscepti-
bilities of C. rugosa to fluconazole and voriconazole, stratified
by geographic region of origin, as determined by CLSI disk
diffusion testing. These isolates were obtained from 115 insti-
tutions in 35 countries. Overall, it is evident that C. rugosa
exhibits decreased susceptibility to both fluconazole and vori-
conazole, with only 40.5% and 61.4% of isolates, respectively,
showing susceptibility to these two triazole antifungal agents.
Susceptibilities to fluconazole were lowest (40%) in the Asia-
Pacific (34.9%) and Latin American (35.7%) regions and high-
est in Europe (75.9%).
Although voriconazole was always more active against C.
rugosa than fluconazole, irrespective of geographic region, the
lowest susceptibilities to this agent (55.8 to 58.8%) were also
observed in the regions with the lowest susceptibilities to flu-
conazole (Table 2). In contrast, 97% to 100% of C. rugosa
isolates from Europe (97.6%) and North America (100%)
were susceptible to voriconazole. These extremes in voricon-
azole susceptibility among isolates of C. rugosa are important
to recognize, especially given previous suggestions (based on
very limited data) that this species was highly susceptible to
voriconazole (6, 9).
Trends in resistance to fluconazole and voriconazole among
C. rugosa isolates over time. Although resistance to fluconazole
among isolates of C. rugosa tested in 2001 was already quite
high (31.7%) (Table 3), more resistance was observed in 2002
and 2003, where 66.0% and 61.2% of isolates, respectively,
TABLE 1. Variation in the frequency of Candida rugosa
by geographic regiona
Region Total no. of Candidaspecies isolates
Total no. (%) of
C. rugosa isolates
Asia-Pacific 17,183 83 (0.4)
Europe 41,187 54 (0.1)
Latin America 11,280 311 (2.7)
North America 6,111 4 (0.1)
Total 75,761 452 (0.6)
a Data were obtained from the ARTEMIS DISK Global Antifungal Surveil-
lance Program from 2001 to 2003. Isolates represent all incident isolates from all
sites of infection.
TABLE 2. Geographic variation in susceptibilities of Candida rugosa






Asia-Pacific Fluconazole 83 34.9 8.4 56.7
Voriconazole 34 58.8 23.5 17.7
Europe Fluconazole 54 75.9 13.0 11.1
Voriconazole 46 97.8 2.2
Latin America Fluconazole 311 35.7 8.4 55.9
Voriconazole 310 55.8 12.9 31.3
North America Fluconazole 4 50.0 25.0 25.0
Voriconazole 4 100.0
Total Fluconazole 452 40.5 9.1 50.4
Voriconazole 394 61.4 12.2 26.4
a All isolates were tested by disk diffusion performed in accordance with CLSI
standard M44-A. S, susceptible, with zone diameters of 19 mm for fluconazole
and 17 mm for voriconazole; R, resistant, with zone diameters of 14 mm for
fluconazole and 13 mm for voriconazole; SDD, susceptible-dose dependent,
with zone diameters of 15 to 18 mm for fluconazole and 14 to 16 mm for
voriconazole.
TABLE 3. Trends in in vitro resistance to fluconazole and
voriconazole among C. rugosa isolates as determined











Fluconazole 186 31.7 150 66.0 116 61.2
Voriconazole 129 3.1 149 38.0 116 38.0
a Data were obtained from the ARTEMIS DISK Surveillance Program, 2001
to 2003.
b Zone (14 mm fluconazole or 13 mm voriconazole) disk diffusion
testing was performed in accordance with CLSI standard M44-A.
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were resistant to fluconazole. Likewise, resistance to voricon-
azole was low in 2001 (3.1%) and was 10-fold higher (38.0%)
in both 2002 and 2003.
Variation in the frequency of isolation and antifungal sus-
ceptibility profile of C. rugosa by clinical service. The clinical
services reporting the isolation of C. rugosa from patient spec-
imens included the hematology-oncology service, the medical
and surgical services, intensive care units (ICUs) (medical,
surgical, and neonatal), and the outpatient service (Table 4).
Those isolates from services with only a few isolates and those
for which a clinical service was not specified were included in
the category “other, not otherwise specified” (NOS).
C. rugosa was isolated most frequently from hospitalized
patients from the medical and surgical services and was less
common from the hematology-oncology, ICU, and outpatient
services. Likewise, isolates from the medical and surgical ser-
vices were the least susceptible to both fluconazole (31.8% and
40.0%, respectively) and voriconazole (44.9% and 67.1%, re-
spectively), whereas the isolates that were the most susceptible
to both agents were seen in the hematology-oncology and
outpatient services (Table 4).
Variation in the frequency of isolation and antifungal sus-
ceptibility profile of C. rugosa by clinical specimen type. The
major specimen types yielding C. rugosa as a putative pathogen
included blood, urine, respiratory, skin, soft tissue, and genital
specimens (Table 5). Those isolates from uncommon specimen
types and those for which a specimen type was not recorded
were grouped under “miscellaneous (Misc.), NOS.”
Aside from the Misc., NOS category, more C. rugosa isolates
were found in blood and urine specimens than in respiratory,
skin, soft tissue, and genital specimens (Table 5). Thus, C.
rugosa most often causes infection in sites common to other
Candida spp. Importantly, isolates of C. rugosa from blood
were considerably less susceptible to both fluconazole (28.4%)
and voriconazole (35.6%) than those from any other specimen
type (Table 5).
DISCUSSION
The results from this large study of C. rugosa both confirm
previous observations regarding this species and refute others
(6, 9). First of all, it does appear, as suggested previously by
TABLE 4. Susceptibility of Candida rugosa to fluconazole and voriconazole by clinical service
Clinical service







Hematology-oncology (4,635) Fluconazole 14 (3.1) 0.3 71.4 21.4 7.1
Voriconazole 11 (2.8) 90.0 9.1
Medical (17,408) Fluconazole 179 (39.6) 1.0 31.8 3.9 64.2
Voriconazole 158 (40.1) 44.9 19.0 36.1
Surgical (5,126) Fluconazole 145 (32.1) 2.8 40.0 9.7 50.3
Voriconazole 140 (35.5) 67.1 10.0 22.9
ICU (10,052) Fluconazole 24 (5.3) 0.2 41.7 12.5 45.8
Voriconazole 10 (2.5) 80.0 10.0 10.0
Outpatient (6,414) Fluconazole 17 (3.8) 0.3 70.6 17.6 11.8
Voriconazole 17 (4.3) 88.2 5.9 5.9
Other, NOS (32,136) Fluconazole 73 (16.1) 0.2 49.3 15.1 36.6
Voriconazole 58 (14.8) 75.9 3.4 20.7
a Total number of Candida isolates from each service.
b Percentage of all C. rugosa isolates tested.
c C. rugosa as a percentage of all isolates from that clinical service.
TABLE 5. Susceptibility of Candida rugosa to fluconazole and voriconazole by specimen type
Specimen type/site







Blood (8,256) Fluconazole 74 (16.4) 0.9 28.4 6.8 64.9
Voriconazole 59 (15.0) 35.6 20.3 44.1
Urine (9,722) Fluconazole 99 (21.9) 1.0 39.4 6.1 54.5
Voriconazole 83 (21.1) 61.4 15.7 22.9
Respiratory (20,274) Fluconazole 41 (9.1) 0.2 46.3 12.2 41.5
Voriconazole 36 (9.1) 63.9 2.8 33.3
Skin/soft tissue (4,986) Fluconazole 23 (5.1) 0.5 47.8 13.0 39.1
Voriconazole 21 (5.3) 66.7 9.5 23.8
Genital (15,831) Fluconazole 20 (4.4) 0.1 75.0 10.0 15.0
Voriconazole 12 (3.0) 100.0
Misc., NOS (16,692) Fluconazole 195 (43.1) 1.2 40.0 10.3 49.7
Voriconazole 183 (46.5) 66.1 10.9 23.0
a Total number of Candida isolates from each specimen type.
b Percentage of all C. rugosa isolates tested.
c C. rugosa as a percentage of all isolates of that specimen type.
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Colombo et al. (2) and Nucci and Marr (6), that the frequency
of C. rugosa as a cause of candidal infections is increasing and
that these infections are especially common in Latin America
(Table 1). Although the apparent “emergence” of C. rugosa
may simply reflect an increasing tendency for clinical labora-
tories to identify isolates of Candida species, one cannot dis-
count the possibility that given the increased numbers of im-
munocompromised individuals worldwide, an ever-increasing
number of previously rare species, such as C. rugosa, are truly
emerging as opportunistic pathogens (6, 9). Furthermore, C.
rugosa does appear to exhibit decreased susceptibility to flu-
conazole, and this pattern varies by geographic region (Table
2). Decreased susceptibility to both polyenes and fluconazole
has been noted previously (1–3, 9), even though data were
based on the testing of relatively few isolates.
Previously reported data regarding the susceptibility of C.
rugosa to voriconazole suggested that this agent was very active
against this species (6, 7, 9). Again, this conclusion was based
on the testing of very small numbers of isolates obtained pri-
marily from North America and Europe. The data presented
herein indicate that C. rugosa should be considered to have
decreased susceptibility to voriconazole as well as fluconazole
(Table 2). This pattern of decreased susceptibility was most
prominent in the Asia-Pacific and Latin American regions (Ta-
ble 2). Voriconazole appeared to be considerably more active
against C. rugosa isolates from Europe and North America.
The reasons for these geographic differences in azole suscep-
tibility are not known; however, the most conservative ap-
proach to dealing with infections caused by C. rugosa would
be to assume decreased susceptibility (e.g., resistance) until
proven otherwise by standardized antifungal susceptibility test-
ing (16). Very few isolates of C. rugosa have been tested against
the echinocandins (7, 9). The few isolates that have been tested
all appear to be susceptible to these agents at clinically achiev-
able concentrations (i.e., 2 g/ml).
In addition to the apparent emergence of C. rugosa as a
cause of clinical infection, there also seems to be a trend
towards the emergence of resistance to fluconazole and vori-
conazole over time (Table 3) (11). Resistance to fluconazole
increased from a baseline rate of 30% to more than 60%
over the course of the study (Table 3). Similarly, resistance to
voriconazole increased from 3.1% in 2001 to 38.0% in 2002
and 2003 (Table 3). These parallel increases in resistance pro-
vide further support for a strong degree of cross-resistance
among the azole class of antifungals. Although little is known
about resistance mechanisms specific to C. rugosa, mechanisms
described for other Candida species include the alteration of
the 14--demethylase target (19) along with the induction of
efflux pump mechanisms (18, 22).
As suggested previously by Colombo et al. (2) and by Rosas
et al. (17), infections due to C. rugosa were most common
among patients hospitalized in the medical and surgical ser-
vices of the participating hospitals (Table 4). Likewise, resis-
tance to both fluconazole and voriconazole was highest among
isolates from these two services. Interestingly, the most sus-
ceptible isolates to both agents were found in the hematology
and oncology services, where one might expect azole drug
pressure to be greatest. Thus, the in vitro susceptibility of this
species to the azole antifungals is not entirely predictable,
suggesting that, as with C. glabrata (9), antifungal susceptibility
testing may play a useful role in optimizing the antifungal
therapy for this organism (8, 20).
Finally, it is important that C. rugosa is most often detected
in bloodstream and urinary tract infections (Table 5). Further-
more, the isolates obtained from blood cultures demonstrated
the highest level of resistance to both agents. This finding
reinforces previously published opinions regarding the impor-
tance of identifying isolates of Candida obtained from blood
and normally sterile-site infections to the species level (8, 9, 16,
20). It should be noted that although isolates of C. rugosa from
blood are clearly pathogenic, the isolation of this or any other
species of Candida from nonsterile sites (e.g., urine, respira-
tory, and genital specimens) may simply represent colonization
rather than infection. We have included isolates of C. rugosa
from sites other than blood based on the clinical assessment of
the local-site investigators that the isolate was associated with
clinical pathology in the respective patient.
In summary, we have used the extensive and validated
database of the ARTEMIS DISK Antifungal Surveillance Pro-
gram (11) to address several gaps in our knowledge of C.
rugosa as an opportunistic pathogen. Our findings suggest that
not only is this species emerging as an agent of invasive fungal
infection, it also appears to be developing increased resistance
to azole antifungal agents, especially in certain geographic
regions. C. rugosa appears to fill the same clinical niche as
other more common species of Candida in that it most often
causes BSI and urinary tract infections in patients hospitalized
in the medical and surgical inpatient services. Notably, BSI
isolates of this species are the least susceptible to both flucon-
azole and voriconazole. Thus, C. rugosa joins the established
pathogens C. glabrata and C. krusei as a species of Candida
with reduced susceptibility to the azole antifungal agents.
These data provide significant new information regarding a
relatively uncommon cause of opportunistic fungal infection
and underscore the value of longitudinal global surveillance
studies such as ARTEMIS.
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